title: Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
abstract: Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). However, recent studies have suggested that there is large inter-individual response variability to these drugs (especially to clopidogrel) and that improved inhibition of platelet reactivity using higher doses or new, more potent agents would further reduce the occurrence of cardiovascular events, but may also increase the risk of bleeding. Many different protocols of antiplatelet therapy have been studied and have shown benefit in reducing the rate of major adverse cardiovascular events after PCI. Therefore, the choice of an appropriate antiplatelet therapy protocol is sometimes difficult for the clinician and should be individualized as per the particular patient risk, accounting for both the risk of recurrent cardiovascular events and bleeding. We review the recent data on efficacy and safety of dosing strategies for antiplatelet therapy in PCI.
authors.affiliation: Pôle de Cardiologie, Hôpital Cardiologique, Service de Cardiologie B et Centre Hémodynamique, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Lemesle
authors.forename: Gabriel
authors.initials: G
authors.lastname: Maluenda
authors.forename: Laurent
authors.initials: L
authors.lastname: Bonello
authors.forename: Cedric
authors.initials: C
authors.lastname: Delhaye
authors.forename: Arnaud
authors.initials: A
authors.lastname: Sudre
authors.forename: Christophe
authors.initials: C
authors.lastname: Bauters
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Lablanche
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002985:Clinical Protocols; D000077144:Clopidogrel; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D018579:Patient Selection; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D017410:Practice Guidelines as Topic; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D018570:Risk Assessment; D012307:Risk Factors; D013876:Thiophenes; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine; D001241:Aspirin